1 / 40

Managing Chemotherapy Toxicities in GI Cancers

Managing Chemotherapy Toxicities in GI Cancers. September 30, 2008. Christine Brezden-Masley, MD PhD FRCPC. To understand toxicities from colorectal cancer therapy gastric cancer therapy To manage toxicities from colorectal cancer therapy gastric cancer therapy. Objectives.

bedros
Télécharger la présentation

Managing Chemotherapy Toxicities in GI Cancers

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Managing Chemotherapy Toxicities in GI Cancers September 30, 2008 Christine Brezden-Masley, MD PhD FRCPC

  2. To understand toxicities from colorectal cancer therapy gastric cancer therapy To manage toxicities from colorectal cancer therapy gastric cancer therapy Objectives

  3. Adjuvant colorectal cancer FOLFOX Xeloda Clinical trial: CRC2 – Stage 3 CRC: FOLFOX +/- Cetuximab (for RAS wt patients) CRC3 – Stage 2 CRC: 18q deletion: FOLFOX +/- Avastin CRC4 – Stage 2-3 Rectal cancer: FOLFOX +/- Avastin Colorectal Cancer

  4. Dose-limiting cold-induced sensory peripheral neuropathy Ask patients if are able to button shirt and write If so, but have tingling >14 days (into next cycle) then decrease dose of oxaliplatin 85 mg/m2 to 65 mg/m2 If pain and significant paresthesia, cannot button shirt, cannot write – discontinue oxaliplatin and continue with FUFA Any prevention studies for neuropathy? FOLFOX

  5. CalMag Infusions

  6. 2008 ASCO

  7. 2008 ASCO

  8. 2008 ASCO

  9. 2008 ASCO

  10. 2008 ASCO

  11. 2008 ASCO

  12. 2008 ASCO

  13. 2008 ASCO

  14. 2008 ASCO

  15. 2008 ASCO

  16. 2008 ASCO

  17. 2008 ASCO

  18. 2008 ASCO

  19. 2008 ASCO

  20. 2008 ASCO

  21. 2008 ASCO

  22. 2008 ASCO

  23. 2008 ASCO

  24. 2008 ASCO

  25. CalMag 2-3 tablets per day without food Stay warm Do not drink cold fluids Neuropathy

  26. FOLFOX Hesketh 4 FOLFIRI Hesketh 4 ECF/ECX Hesketh 5 Xeloda (Capecitabine) Hesketh 2 Nausea and Vomiting

  27. Immediate Zofran 8mg po BID Decadron 8 mg po BID X 3 days with chemotherapy Delayed Stemetil Maxeran Nausea and Vomiting

  28. IV hydration at home CCAC daily IV hydration with NS 600ml/day Marinol/Nabilone (cannabinoid) Haldol Aprepitant Cost Zyprexa (olanzapine) Delayed N/V

  29. FOLFOX FOLFIRI Imodium Loperamide NO MAXIMUM for chemotherapy-induced diarrhea Ensure no C.Difficile (ischemic gut) Somatostatin (100 mg sc x1) Diarrhea

  30. Immediate diarrhea (during infusion) SN38 active metabolite Cholinergic response Treatment with Atropine 0.2 mg sc x1 Morphine (cramping) FOLFIRI

  31. No role for primary prevention of GCSF FOLFIRI>FOLFOX ECF/ECX For CURATIVE intent Can treat with GCSF – funding an issue If private insurance – can use in advanced care to push doses Myelosuppression

  32. If febrile neutropenia Not difficult for Section 8 to fund FOLFOX and Gemcitabine Thrombocytopenia If platelets <85 should dose-reduce Educate patient about bleeding risk Anemia Check for Fe stores – supplement Role for ESAs? Myelosuppression

  33. Hand-Foot Syndrome Keep hands and feet moist with Udder cream May reduce dose if continues (blistering and desquamation and pain) Diarrhea Mucositis XELODA

  34. Good oral hygeine critical Baking soda rinses – ½ teaspoon of baking soda in half glass of water daily 2-3x If severe neutropenia – than mucositis usually occurs Nystatin (Nilstat) 500,000 Units po q4-6 hours (swish and swallow) Tantum (ODB) Butlers/Blacksteins mouth wash Mucositis

  35. Dihydropyrimidine dehydrogenase (DPD) Catabolic pathway of 5-FU Responsible for 85% of degradation of 5-FU 5-FU 5-FUTP 5-FdUMP (ACTIVE form) DPD deficiency 3-5% population (polymorphisms as high as 8%) Autosomal recessive DPD

  36. DPD Deficiency Syndrome Grade 4 neutropenia Severe/fatal diarrhea Mucositis/stomatitis Rash Can happen after 1st or 2nd dose of 5-FU Treatment Supportive care DPD Deficiency

  37. Shape your practice – you’re the boss Do not need to examine patient at each chemotherapy session – but need to MONITOR ALL BLOODWORK MONITOR SIDE-EFFECTS ASK PATIENT HOW THEY’RE DOING FATIGUE/ENERGY APPETITE MOOD Clinical Pearls

  38. NEED TO ASSESS PATIENT Pain New symptoms/signs Dehydration Neurologic Major organ involvement Respiratory (r/o PE) Cardiac (electrolyte disturbances) Renal Hepatic (Ascites) CLINICAL PEARLS

  39. Thanks Questions? brezdenc@smh.toronto.on.ca

More Related